Protease Inhibitors: Developing evolution-resistant drugs for COVID-19

Analyzing how mutations affect the main protease of SARS-CoV-2 may help researchers develop drugs that are effective against current and future variants of the virus.
  • Download
  • Cite
  • CommentOpen annotations (there are currently 0 annotations on this page).
  1. Daniel M Weinreich  Is a corresponding author
  1. Department of Ecology, Evolution and Organismal Biology, Brown University, United States
  2. Center for Computational Molecular Biology, Brown University, United States

As of mid-July 2022, more than 12 billion doses of vaccines against SARS-CoV-2, the virus responsible for COVID-19, have been administered to over 5 billion individuals (WHO, 2022). However, mutations that allow the virus to evade vaccines are spreading globally, leading to a need for boosters and updated vaccines (Callaway, 2021; Vogel, 2022). This immunity ‘arms race’ illustrates how efforts to control the COVID-19 pandemic could benefit from additional pharmaceutical approaches.

One of these approaches is the use of inhibitor drugs to block the action of viral proteases, the enzymes that cleave polyproteins encoded in the viral genome to yield several functional proteins. If these proteases are inactivated, the virus cannot synthesize the proteins it requires to reproduce, so inhibiting these enzymes may be an effective way of treating viral diseases. For example, protease inhibitors are key components of highly active antiretroviral therapy (HAART), which renders HIV a chronic disease.

In the case of SARS-CoV-2, many inhibitor candidates have been identified for its main protease, which is called Mpro (Jin et al., 2020; Narayanan et al., 2022). One of these inhibitors, with the trade name Paxlovid, has been authorized for emergency use by the United States Federal Drugs Administration (FDA), and pharmacists have been allowed to prescribe it since July 2022 (Owen et al., 2021; FDA, 2022). But can Mpro inhibitors be designed to avoid the rapid obsolescence we have observed in vaccines as a result of viral evolution? Now, in eLife, Julia Flynn, Daniel Bolon and colleagues at the University of Massachusetts (UMass) Chan Medical School and the Novartis Institutes for Biomedical Research report the results of experiments assessing the effects of different mutations on the proteolytic activity of MPro (Flynn et al., 2022).

Using a method called deep mutational scanning (Fowler and Fields, 2014), Flynn et al. generated a ‘library’ that contained almost every single missense mutation of the Mpro enzyme relative to the sequence found in the original Wuhan isolate (Wu et al., 2020). Missense mutations are changes to a single nucleotide in the sequence that alter the resulting amino acid. Assessing the activity of the MPro variants that result from each conceivable missense mutation revealed how they each affect the activity of the enzyme. To do this, Flynn et al. placed the library into yeast cells, and assessed how well each variant of the protease worked in three different environments.

The results showed that the proteolytic activity of each variant was correlated across the three assays, implying that the assays capture the same properties of MPro. Flynn et al. also found a correlation between the results of their assays and previous measurements of the catalytic rates for individual variants. Additionally, the vast majority of the 290 missense mutations of MPro observed most frequently (at least 100 times) in COVID-19 patients exhibited activity comparable to that of the wild type. This further confirmed that Flynn et al.’s assay captures the biologically relevant function of the enzyme. Finally, the team found that all of the mutation-intolerant residues in MPro (the sites at which at least 17 out of the 20 alternative amino acids block the protein’s activity) are highly conserved in other coronaviruses. This suggests that inhibitors designed against the current SARS-CoV-2 form of the enzyme will likely be active against future, emergent outbreaks.

Most protease inhibitors act by competitively occupying the enzyme’s binding pocket to the exclusion of its native substrate. Therefore, Flynn et al. decided to further analyze missense mutations in the vicinity of the binding pocket that nevertheless preserve enzyme activity, reasoning that these mutations might represent opportunities for the virus to evolve resistance to inhibitors. Unfortunately, they found that mutations at many of those residues preserve the proteolytic ability of Mpro (Cho et al., 2021).

Similarly, and perhaps of more immediate concern, Flynn et al. identified three missense mutations that reduced the binding stability to Paxlovid by at least 1 kcal/mol, corresponding to an approximately five-fold reduction in the drug’s binding affinity, while maintaining proteolytic activity. These represent likely resistance mutations; indeed, a subset of these mutations have now been observed in laboratory populations of SARS-CoV-2 challenged with this version of Paxlovid, as well as in currently circulating isolates (Service, 2022). It will be important to monitor the frequency of these three mutations in patients being treated with Paxlovid as its use becomes more widespread.

But the potential implications of the findings of Flynn et al. go further than providing insight into prospects for resistance evolution against existing Mpro inhibitors. Some years ago, the notion of the ‘substrate envelope’ of a viral protease – the overlapping volume occupied by all of its native substrates – was introduced (King et al., 2004). The inspiration was that the substrate specificity of the HIV protease seemed to be determined by the shape of the substrate rather than by a specific amino acid sequence. Because resistance mutations must allow an enzyme to distinguish between its inhibitors and its substrates, they might work by introducing atomic overlaps or disfavored electrostatics in the region where the inhibitor protrudes beyond the substrate envelope. In a recent companion study, researchers at UMass and Novartis (including many authors from Flynn et al.) have reported a high-resolution structure of the SARS-CoV-2 Mpro substrate envelope (Shaqra et al., 2022).

Together, these two articles provide clear guidance for the development of evolution-resistant protease inhibitors against SARS-CoV-2. To find clinically durable candidates, compounds should be screened first to identify those that lie entirely within the enzyme’s substrate envelope. Of these, care should be taken to select those that interact with one or more mutation-intolerant residues. This will make it more difficult for the protease to evolve the ability to discriminate between its native substrates and the drug without blocking its activity. Of course, Darwinian evolution is a tremendously powerful force, and resistance has evolved against every antimicrobial class ever deployed in the clinic. Nevertheless, the functional and structural resolution now available for Mpro-inhibitors offers new optimism 30 months into the COVID-19 pandemic.

References

  1. Website
    1. WHO
    (2022) WHO Coronavirus (COVID-19) Dashboard
    Accessed July 6, 2022.

Article and author information

Author details

  1. Daniel M Weinreich

    Daniel M Weinreich is in the Department of Ecology, Evolution and Organismal Biology, and the Center for Computational Molecular Biology, Brown University, Providence, United States

    For correspondence
    daniel_weinreich@brown.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1424-7541

Publication history

  1. Version of Record published:

Copyright

© 2022, Weinreich

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Download links

Further reading

    1. Evolutionary Biology
    Ljiljana Mihajlovic, Bharat Ravi Iyengar ... Yolanda Schaerli
    Research Article

    Gene duplication drives evolution by providing raw material for proteins with novel functions. An influential hypothesis by Ohno (1970) posits that gene duplication helps genes tolerate new mutations and thus facilitates the evolution of new phenotypes. Competing hypotheses argue that deleterious mutations will usually inactivate gene duplicates too rapidly for Ohno’s hypothesis to work. We experimentally tested Ohno’s hypothesis by evolving one or exactly two copies of a gene encoding a fluorescent protein in Escherichia coli through several rounds of mutation and selection. We analyzed the genotypic and phenotypic evolutionary dynamics of the evolving populations through high-throughput DNA sequencing, biochemical assays, and engineering of selected variants. In support of Ohno’s hypothesis, populations carrying two gene copies displayed higher mutational robustness than those carrying a single gene copy. Consequently, the double-copy populations experienced relaxed purifying selection, evolved higher phenotypic and genetic diversity, carried more mutations and accumulated combinations of key beneficial mutations earlier. However, their phenotypic evolution was not accelerated, possibly because one gene copy rapidly became inactivated by deleterious mutations. Our work provides an experimental platform to test models of evolution by gene duplication, and it supports alternatives to Ohno’s hypothesis that point to the importance of gene dosage.

    1. Evolutionary Biology
    Lucy A Winder, Mirre JP Simons, Terry Burke
    Research Article

    Life-history theory, central to our understanding of diversity in morphology, behaviour, and senescence, describes how traits evolve through the optimisation of trade-offs in investment. Despite considerable study, there is only minimal support for trade-offs within species between the two traits most closely linked to fitness – reproductive effort and survival – questioning the theory’s general validity. We used a meta-analysis to separate the effects of individual quality (positive survival/reproduction correlation) from the costs of reproduction (negative survival/reproduction correlation) using studies of reproductive effort and parental survival in birds. Experimental enlargement of brood size caused reduced parental survival. However, the effect size of brood size manipulation was small and opposite to the effect of phenotypic quality, as we found that individuals that naturally produced larger clutches also survived better. The opposite effects on parental survival in experimental and observational studies of reproductive effort provide the first meta-analytic evidence for theory suggesting that quality differences mask trade-offs. Fitness projections using the overall effect size revealed that reproduction presented negligible costs, except when reproductive effort was forced beyond the maximum level observed within species, to that seen between species. We conclude that there is little support for the most fundamental life-history trade-off, between reproductive effort and survival, operating within a population. We suggest that within species the fitness landscape of the reproduction–survival trade-off is flat until it reaches the boundaries of the between-species fast–slow life-history continuum. Our results provide a quantitative explanation as to why the costs of reproduction are not apparent and why variation in reproductive effort persists within species.